The invention relates to 3,5-dioxo-(2H,4H)-1,2,4-triazine compounds of formula I ##STR00001## in which the variables are defined herein, as well as additive salts with pharmaceutically acceptable bases and the various enantiomers of compounds having asymmetrical carbons, as well as their mixtures in all proportions, including racemic mixtures in particular.